Evidence map›Paper›PMID 42844527›Full record

ArticleAnnals of surgical oncology2026

Impact of Systematic Discontinuation of Mitomycin C HIPEC for Colorectal Peritoneal Metastases on Oncologic Outcomes: A Propensity Score-Matched Analysis.

M Daniyal Tanweer, Muhammad Talha Waheed, Isaac B Paz, Thinzar Lwin, Hamza Mohammed, Laleh Melstrom, Yuman Fong, Gagandeep Brar, Dani Castillo, Pashtoon Murtaza Kasi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M Daniyal TanweerDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Muhammad Talha WaheedDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Isaac B PazDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Thinzar LwinDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Hamza MohammedDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Laleh MelstromDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Yuman FongDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Gagandeep BrarDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Dani CastilloDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Pashtoon Murtaza KasiDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Marwan FakihDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Mustafa RaoofDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA. mraoof@coh.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe PRODIGE7 trial demonstrated a lack of effectiveness of oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for colorectal cancer peritoneal metastases (CRC-PM), prompting many centers to transition to mitomycin C (MMC)-based HIPEC. However, the oncologic benefit of MMC-HIPEC remains unclear.

methodsIn 2021, our  center systematically discontinued HIPEC for CRC-PM. We  retrospectively compared consecutive patients who underwent MMC-HIPEC after complete CRS (2009-2021) with those undergoing CRS alone (2021-2024). Outcomes included recurrence-free survival (RFS), peritoneal RFS, and 90-day postoperative outcomes. Propensity score-matching was performed using age, sex, primary tumor location, extraperitoneal disease, completeness of cytoreduction score, peritoneal carcinomatosis index, and preoperative chemotherapy.

resultsThe study included 107 consecutive patients (median age, 56 years; median peritoneal carcinomatosis index [PCI], 8; 48% male; 45% left-sided primary tumor), 68 (64%) of whom underwent CRS-HIPEC with MMC. Most of the patients (75%) experienced recurrence. After matching, 96 patients remained (32 treated with CRS alone; 64 treated with CRS-HIPEC). Between CRS alone and CRS-HIPEC, RFS was comparable (median, 8.4 months [95% confidence interval {CI}, 5.6-12.7 months] vs. 8.7 months [95% CI, 6.2-11.0 months]; p = 0.527), as was peritoneal RFS (median 12.7 months [95% CI, 8.4-not reached {NR}] vs. 14.2 [95% CI, 8.7-19.8 months]; p = 0.806). The CRS-HIPEC patients had more respiratory complications (0% vs. 13%; p = 0.037) and longer hospital stays (median, 10 vs. 7 days; p < 0.001). Exploratory analyses suggested benefit in node-negative disease.

conclusionOmission of MMC-HIPEC did not compromise oncologic outcomes.

Identifiers

PMID42844527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.